We have written about the promise of gene therapy to correct genetic disease many times. An exciting development happened ...
NEW YORK – Azalea Therapeutics launched on Tuesday, having raised $82 million in seed and Series A financing to develop in vivo genetic medicines for cancer and autoimmune conditions using its ...
The grantmaking organization Open Philanthropy has awarded funding for a University of California San Diego technology ...
Recognized in the Biotechnology category of the 2025 Top Innovations contest, small Cas12l nucleases are versatile, ...
Amazon S3 on MSN
How gene editing could reshape the future of humans
CRISPR technology could one day create “designer babies, ” raising major ethical and social inequality concerns.
In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the approach ...
Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, today announced its official launch and completion of $82 million in seed and Series A financing to ...
We’ve gone from asking, “How can we afford to make more videos?” to “How do we make sure the ones we already made are ...
A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...
It is a smart strategy to diversify your portfolio by investing in high-quality companies built on proven technologies.
Pairwise has licensed its Fulcrum® gene editing platform to the International Rice Research Institute (IRRI), a non-profit agricultural research organization. The agreement will enable IRRI to apply ...
Gene editing techniques, including CRISPR, prime editing, and nucleases, allow scientists to tackle genetic diseases, cancer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback